Supportive Care | Specialty

The supportive care condition center is a comprehensive resource for clinical news and expert insights on supportive care. Read more at OncLive.

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer

October 30th 2024

The FDA has received an NDA seeking the approval of a 3-month formulation of leuprolide mesylate for advanced prostate cancer.

The OncFive: Top Oncology Articles for the Week of 9/1

September 7th 2024

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

ASCO Palliative Care Expert Panel Provides Recommendations to Integrate Health Equity Into Guideline Development

September 4th 2024

The ASCO Palliative Care Expert Panel has offered recommendations to add health equity measures to their palliative care and other future guidelines.

Clinically Guided Cannabis Use Helps Mitigate Symptoms Experienced by Patients With Cancer

August 1st 2024

Blake Zenger, MBA, and Brooke Worster, MD, MS, FACP, highlight the importance of personalized cannabis use in alleviating treatment-related symptoms.

Model Validates Cost Savings With Cannabis in Mitigating Symptoms for Patients With Cancer

July 31st 2024

Blake Zenger, MBA, and Brooke Worster, MD, MS, FACP, detail a health care cost impacts model pertaining to the use of cannabis for therapy-related symptoms

Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy

July 23rd 2024

Crofelemer did not improve the incidence of diarrhea in patients with solid tumors receiving targeted therapy.

Oncologic Supportive Care Is Absolutely Critical—But How Do We Define It?

June 7th 2024

Defining the goals of a clinical team within a cancer program or oncology practice group, where the focus will be on maximizing QOL, may be difficult.

Non-Pharmacologic Therapies for Pain Management in Patients With Cancer: Opportunities and Challenges

May 27th 2024

Janet Abrahm, MD, FACP, FAAHPM, reviews the standing of the role of integrative therapies in cancer care.

Epidemiology, Treatment of an Aging Inflammatory Bowel Disease Population

April 22nd 2024

Adam S. Faye, MD, of NYU Grossman School of Medicine, discusses the epidemiology and treatment for aging patients with inflammatory bowel disease.

The New Frontier With Integrative Oncology: Shooting for the Stars

April 11th 2024

Richard T. Lee, MD, and Edward S. Kim, MD, MBA, discuss the benefits of integrative oncology and exploring integrative approaches at the Cherng Family Center for Integrative Oncology at City of Hope.

A Medical Oncologist’s Insights on Cannabis Use in the Care of Patients With Hematologic Malignancies

April 2nd 2024

Lindsay Wilde, MD, explains when cannabis may be appropriate and how she’s seen the agent affect quality of life for her patients.

Unpacking the Role of Cannabis in Oncology as Reclassification of the Drug Pends

March 29th 2024

Brooke Worster, MD, MS, FACP, and chief medical officer at EO Care, details what oncologists should know about medical cannabis pending the expectant marijuana reclassification from a Schedule I to a Schedule III drug.

FDA Approves 2 Denosumab Biosimilars for All Reference Medicine Indications

March 5th 2024

The FDA has approved the biosimilars denosumab-bddz (Wyost) and denosumab-bddz (Jubbonti) for use in all indications of the reference medicines denosumab (Xgeva) and denosumab (Prolia).

FDA Grants Orphan Drug Designation to LUT014 for EGFR Inhibitor–Induced Rash

February 28th 2024

The FDA granted an orphan drug designation to LUT014 for the treatment of EGFR inhibitor–induced acneiform rash.

FDA Approves Delivery System of Biosimiliar Pegfilgrastim-cbqv for Febrile Neutropenia

December 26th 2023

The FDA has approved an on-body injector (OBI) presentation of the biosimilar pegfilgrastim-cbqv biosimilar (Udencya), known as Udencya Onbody, which is administered to patients with cancer the day after chemotherapy in order to decrease infection incidence from febrile neutropenia.

Talazoparib Plus Enzalutamide Has Manageble Toxicity With Dose Modifications, Supportive Care in mCRPC

June 3rd 2023

The use of talazoparib plus enzalutamide was manageable with dose modifications or standard supportive care treatment in patients with metastatic castration-resistant prostate cancer.

Chinese Phase 3 Trial of Roxadustat in Non-Myeloid Malignancies Meets Primary End Point

May 18th 2023

Roxadustat proved to be noninferior to recombinant erythropoietin alfa with regard to change in hemoglobin level from baseline to an average level during weeks 9 to 13 in patients receiving concurrent chemotherapy for non-myeloid malignancies in China, meeting the primary end point of an ongoing phase 3 trial.

Demystifying the Role of Palliative Care in the Oncology Clinic

January 27th 2023

Despite American Society of Clinical Oncology guidelines calling for introduction of palliative care early in the course of disease, these services remain underused.

Forging a New Field

November 25th 2022

Almost single-handedly, Jennifer Temel, MD, defined a research field in medicine, creating a new focus on quality of life for patients and survivors.

FDA Greenlights Leuprolide Acetate Injection for Palliative Treatment in Advanced Prostate Cancer

November 2nd 2022

The FDA has approved leuprolide acetate injection for use in the palliative treatment of patients with advanced prostate cancer.